BioFlyte is a technology company.
BioFlyte has raised $11.0M across 2 funding rounds.
BioFlyte has raised $11.0M in total across 2 funding rounds.
BioFlyte is a biothreat security company developing fieldable aerosol mass spectrometers for real-time detection and identification of biological and chemical threats like Anthrax, Ricin, viruses, spores, and aerosolized Fentanyl.[1][2][3] It serves critical infrastructure operators, government agencies, airports, and mail screening services by protecting against biohazards and chemical toxins without relying on expensive reagents, enabling autonomous operation for months.[1][2][4] The company's growth includes $12.8M in total funding, partnerships with entities like Pittsburgh International Airport and the Pentagon Force Protection Agency, and a recent U.S. Department of Homeland Security SAFETY Act Designation in August 2025, positioning it for market penetration in high-stakes environments like major U.S. airports.[2][3][5]
BioFlyte, headquartered in Albuquerque, New Mexico, commercializes miniaturized, low-cost, low-power mass spectrometers originally rooted in advanced biodefense technologies for airborne microbial and toxin detection.[3][4] Led by President & CEO Todd Sickles and Chief Science Officer Wayne Bryden, Ph.D., the company has deep ties to New Mexico's tech ecosystem, including local government labs and Sandia Science & Technology Park.[1][4][5] Its evolution focuses on critical infrastructure protection and pandemic response, with early traction from evaluations by defense agencies and commercial partners like SoBran, Inc., culminating in the BioTOF™ system's deployment for mail screening and airport security.[2][3][5]
BioFlyte rides the surging demand for biothreat surveillance amid rising geopolitical tensions, pandemics, and synthetic opioid crises, enabling point-of-need detection in transportation hubs, mailrooms, and public venues.[1][2][3] Timing aligns with post-COVID infrastructure investments and U.S. homeland security priorities, as seen in its DHS designation and airport expansion goals.[1][5] Market forces like fentanyl aerosol risks and bioterrorism threats favor its reagent-free, real-time edge over legacy systems, influencing the ecosystem by partnering with labs and agencies to set new standards for scalable chem/bio defense.[2][4][5]
BioFlyte's near-term priority is securing at least one major U.S. airport contract within 12 months, leveraging its New Mexico roots for talent and partnerships to drive revenue beyond $5M recent funding.[1][3] Escalating global bio-risks and AI-enhanced threat libraries will shape its path, potentially expanding to more commercial sites and international markets. As a validated player in biodefense, BioFlyte could redefine critical infrastructure protection, scaling its "revolutionary" spectrometers from niche security to widespread biosecurity at scale.[2][5]
BioFlyte has raised $11.0M in total across 2 funding rounds.
BioFlyte's investors include New York Ventures, Salesforce Ventures, Scout Ventures, Cottonwood Technology Fund, Mountain Group Partners.
BioFlyte has raised $11.0M across 2 funding rounds. Most recently, it raised $5.0M Series B in August 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2023 | $5.0M Series B | New York Ventures, Salesforce Ventures, Scout Ventures | |
| Apr 1, 2022 | $6.0M Series A | Cottonwood Technology Fund, Mountain Group Partners |